Avadel Q1 2022 Earnings Report
Key Takeaways
Avadel Pharmaceuticals reported a net loss of $26.4 million, or ($0.45) per diluted share, for the quarter ended March 31, 2022. The company's cash, cash equivalents, and marketable securities were $123.5 million as of March 31, 2022. The company continues to work with the FDA to complete the review of its NDA for FT218.
NDA for FT218 continues in late-stage review.
Belief in the full approvability of FT218 based on interactions with the FDA to date.
Presented important interim results from the ongoing open-label RESTORE study of FT218.
Cash, cash equivalents and marketable securities were $123.5 million as of March 31, 2022.
Avadel
Avadel
Forward Guidance
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.